azacitidine has been researched along with thalidomide in 106 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 34 (32.08) | 29.6817 |
| 2010's | 70 (66.04) | 24.3611 |
| 2020's | 2 (1.89) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| List, AF | 3 |
| Galili, N; Mehdi, M; Mumtaz, M; Qawi, H; Raza, A | 1 |
| Nimer, SD | 1 |
| Fortenbaugh, C | 1 |
| Thomas, ML | 1 |
| Steensma, DP; Tefferi, A | 1 |
| Deeg, HJ; Mhyre, AJ | 1 |
| Schiffer, CA | 1 |
| Sloand, EM | 1 |
| Garcia-Manero, G; Jagasia, M; Yang, AS | 1 |
| Ozawa, K | 1 |
| Mitani, K | 1 |
| Ali, F; Galili, N; Lascher, S; Mehdi, M; Mumtaz, M; Raza, A | 1 |
| Miyazawa, K | 1 |
| Cosler, LE; Ferro, SA; Greenberg, PL; Lyman, GH | 1 |
| Nomdedeu, B | 1 |
| Stone, RM | 2 |
| Estey, E; Scott, BL | 1 |
| Gore, SD | 1 |
| Blum, S; Gattermann, N; Germing, U; Haas, R; Habersang, K; Kuendgen, A; Möller, I | 1 |
| Basile, FG | 1 |
| Garcia-Manero, G; Lyons, RM; Sekeres, M; Stone, R | 1 |
| Fenaux, P; Itzykson, R | 1 |
| Galili, N; Raza, A | 2 |
| Scott, BL | 1 |
| Gotlib, J; Greenberg, PL | 1 |
| Ishikawa, T | 2 |
| Sekeres, MA | 1 |
| Afable, M; Cuthbertson, D; Ganetsky, R; Ganetzky, R; Latham, D; List, AF; Loughran, TP; Maciejewski, JP; Paquette, R; Paulic, K; Saba, HI; Sekeres, MA | 1 |
| Lachs, MS; Ritchie, EK | 1 |
| Koppel, A; Schiller, G | 1 |
| Hofmann, WK; Nolte, F | 1 |
| Tefferi, A | 1 |
| Afable, M; Englehaupt, R; List, AF; Maciejewski, JP; O'Keefe, C; Paulic, K; Sekeres, MA | 1 |
| Fenaux, P; Garcia-Manero, G | 1 |
| Baer, MR; Gojo, I | 1 |
| Sanchez, JF | 1 |
| Horiike, S; Kuroda, J; Nagoshi, H; Taniwaki, M | 1 |
| Garcia-Manero, G | 2 |
| Tohyama, K | 2 |
| Gorin, NC; Isnard, F; Malak, S; Perot, C; Rubio, MT; Scherman, E | 1 |
| Abdel-Wahab, O; Berube, C; Bhattacharya, S; Coutre, S; Figueroa, ME; Gallegos, L; Gotlib, JR; Kohrt, HE; Levine, R; Liedtke, M; Medeiros, BC; Melnick, A; Mitchell, BS; Pollyea, DA; Zehnder, J; Zhang, B | 1 |
| Miyazaki, Y | 2 |
| Chen, JW; Li, XF; Wang, LX; Wen, HY; Zhang, XY | 1 |
| Alimena, G; Breccia, M; Colafigli, G; Federico, V; Finsinger, P; Latagliata, R; Loglisci, G; Petrucci, L; Salaroli, A; Santopietro, M; Serrao, A | 1 |
| Cluzeau, T; Fenaux, P | 1 |
| Chung, HM; Clark, WB; Hazlett, AF; Kmieciak, M; Manjili, MH; McCarty, JM; Payne, KK; Roberts, CH; Sabo, RT; Sanford, K; Toor, AA; Williams, DC | 1 |
| Abboud, CN; Bernabe, N; Cashen, AF; DiPersio, JF; Monahan, R; Ramsingh, G; Stockerl-Goldstein, K; Uy, GL; Vij, R; Westervelt, P | 1 |
| Brower, V | 1 |
| Advani, AS; Afable, M; Cuthbertson, D; Englehaupt, R; Jerez, A; Juersivich, J; Komrokji, R; Lancet, J; List, AF; Maciejewski, JP; Makishima, H; Paleveda, J; Paquette, R; Sekeres, MA; Tabarroki, A; Tiu, RV; Visconte, V | 1 |
| Blaise, D; Charbonnier, A; Gelsi-Boyer, V; Mozziconacci, MJ; Prebet, T; Vey, N | 1 |
| Abdel-Wahab, O; Berube, C; Coutre, S; Gallegos, L; Gotlib, JR; Greenberg, P; Levine, R; Liedtke, M; Medeiros, BC; Mitchell, BS; Pollyea, DA; Zehnder, J; Zhang, B | 1 |
| Rizzieri, DA | 1 |
| Bornhäuser, M; Braulke, F; Bug, G; Ehninger, G; Germing, U; Giagounidis, A; Götze, K; Haase, D; Hofmann, WK; Kündgen, A; Naumann, R; Neesen, J; Platzbecker, U; Röllig, C; Schönefeldt, C; Shirneshan, K; Wermke, M | 1 |
| Matsumura, I; Morita, Y; Tanaka, H | 1 |
| Blau, IW; Böhme, A; Braulke, F; Brümmendorf, TH; Bug, G; Detken, S; Ganster, C; Germing, U; Giagounidis, AA; Götze, K; Haase, D; Hofmann, WK; Jentsch-Ullrich, K; Jung, K; Lübbert, M; Metz, M; Müller-Thomas, C; Ottmann, O; Pfeiffer, S; Platzbecker, U; Schafhausen, P; Schanz, J; Schlenk, RF; Schmidt, B; Seraphin, J; Shirneshan, K; Stadler, M; Trümper, L | 1 |
| Germing, U; Platzbecker, U | 1 |
| Gore, SD; Komrokji, RS; Zeidan, AM | 1 |
| Breda, L; Gambari, R; Rivella, S; Zuccato, C | 1 |
| Kharfan-Dabaja, MA; Komrokji, RS; Zeidan, AM | 1 |
| Govindaraj, C; Kong, YY; Madondo, M; Plebanski, M; Tan, P; Wei, A | 1 |
| Schleiffenbaum, BE | 1 |
| Kizaki, M | 1 |
| Duong, VH; Komrokji, RS; List, AF | 1 |
| Meers, S | 1 |
| Usuki, K | 1 |
| Avery, S; Fleming, S; Govindaraj, C; McManus, J; Patil, S; Perruzza, S; Plebanski, M; Spencer, A; Stevenson, W; Tan, P; Wei, A | 1 |
| Klimek, V | 1 |
| Mukherjee, S; Ornstein, MC; Sekeres, MA | 1 |
| Chen, RL; Huang, BT; Li, BS; Zeng, QC; Zhao, WH | 1 |
| Ali, A; Itzykson, R; Loiseau, C | 1 |
| Braulke, F; Ganster, C; Haase, D; Platzbecker, U; Salinas-Riester, G; Schanz, J; Shirneshan, K | 1 |
| Berube, C; Cardone, MH; Coutre, S; Doykan, C; Garcia, JS; Gotlib, J; Greenberg, P; Hewitt, R; Liedtke, M; McMillan, A; Medeiros, BC; Narayan, R; Percival, ME; Regan, K; Williamson, C | 1 |
| DeZern, AE | 1 |
| Borthakur, G; Bueso-Ramos, C; Cortes, JE; Daver, N; DiNardo, CD; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, HM; Konopleva, M; Patel, KP; Pemmaraju, N; Pierce, S; Ravandi, F; Wierda, W; Yang, H | 1 |
| Al Ali, NH; Bart-Smith, E; Craig, BM; Epling-Burnette, PK; Komrokji, RS; Kordasti, S; Kulasekararaj, A; Lancet, JE; List, AF; Mufti, GJ; Padron, E; Pinilla-Ibarz, J; Zhang, L | 1 |
| Aiba, K; Hayashi, K; Homma, S; Ito, M; Kamata, Y; Kan, S; Nagasaki, E | 1 |
| Cowan, L; Filshie, R; Hertzberg, M; Ho, SJ; Kenealy, M; Link, E; Mills, T; Nicol, A; Patton, N; Prosser, I; Seymour, JF; Zannino, D | 1 |
| Braester, A; Ellis, M; Filanovsky, K; Goldschmidt, N; Herishanu, Y; Kirgner, I; Mittelman, M; Ofran, Y; Oster, HS; Perri, C; Raanani, P; Rosenbaum, H | 1 |
| Carraway, HE | 1 |
| Ando, T; Kimura, S; Kizuka, H; Kojima, K; Kubota, Y; Kusaba, K; Nishioka, A; Sano, H; Shindo, T; Ureshino, H | 1 |
| Stahl, M; Zeidan, AM | 1 |
| Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E | 1 |
| Appelbaum, FR; Atallah, E; Attar, EC; Bloomfield, CD; Buckstein, R; Cook, EK; Cull, AH; Erba, HP; Fang, M; Gaur, R; Gore, SD; List, AF; Litzow, MR; Moseley, A; Nazha, A; Odenike, O; Othus, M; Rauh, MJ; Roulston, D; Sekeres, MA; Stone, RM; Velasco, MR; Zhang, Y | 1 |
| Banos, A; Béné, MC; Bernard, M; Bonmati, C; Bouscary, D; Carré, M; Choufi, B; Couturier, MA; Daguindau, E; Delaunay, J; Dreyfus, F; Fornecker, LM; Hamel, JF; Himberlin, C; Hunault-Berger, M; Ifrah, N; Lissandre, S; Luquet, I; Maillard, N; Marolleau, JP; Ojeda-Uribe, M; Orsini-Piocelle, F; Pigneux, A; Puyade, M; Recher, C; Rouillé, V; Saad, A; Sanhes, L; Schmidt-Tanguy, A; Sutton, L; Tavernier, E | 1 |
| Guruli, G; Matchavariani, K; Mchedlishvili, K; Mitskevich, N; Tsertsvadze, T | 1 |
| Binder, G; Broder, MS; Chang, E; Cogle, CR; McGuire, M; Papoyan, E; Reddy, SR | 1 |
| Dodillet, H; Kreuzer, KA; Monsef, I; Skoetz, N | 1 |
| Thakral, B; Wang, SA | 1 |
| Asmar, F; Christensen, J; Dimopoulos, K; Fibiger Munch-Petersen, H; Gimsing, P; Grønbaek, K; Hermansen, NEU; Liang, G; O'Connel, C; Sjö, L; Sommer Kristensen, L; Søgaard Helbo, A | 1 |
| Kiselev, P; Ma, X; Scott, BL; Steensma, DP; Sugrue, MM; Swern, AS | 1 |
| Gattermann, N; Germing, U; Kaivers, J; Kobbe, G; Kündgen, A; Schroeder, T | 1 |
| Li, Q; Liu, K; Yang, S; Zeng, Q; Zheng, F; Zhou, Z | 1 |
45 review(s) available for azacitidine and thalidomide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
New approaches to the treatment of myelodysplasia.
Topics: Amifostine; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Enzyme Inhibitors; Humans; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Prognosis; Proto-Oncogene Mas; Risk Factors; Severity of Illness Index; Thalidomide; Topotecan; Treatment Outcome | 2002 |
Translational research in myelodysplastic syndromes.
Topics: Angiogenesis Inhibitors; Apoptosis; Azacitidine; Bone Marrow; Cell Death; Enzyme Inhibitors; Humans; Myelodysplastic Syndromes; Neovascularization, Pathologic; Thalidomide | 2004 |
Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Topics: Anemia, Hypochromic; Azacitidine; Bone Marrow; Chromosome Aberrations; Chromosomes, Human, Pair 5; Erythrocyte Transfusion; Erythropoiesis; Erythropoietin; Gene Deletion; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Predictive Value of Tests; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Thalidomide | 2006 |
MDS: navigating the complex course.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Transplantation; Combined Modality Therapy; Humans; Immunosuppressive Agents; Lenalidomide; Medical History Taking; Myelodysplastic Syndromes; Neoplasm Staging; Nurse's Role; Nursing Assessment; Oncology Nursing; Physical Examination; Thalidomide | 2006 |
Strategies for achieving transfusion independence in myelodysplastic syndromes.
Topics: Anemia; Antilymphocyte Serum; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Drug Costs; Erythrocyte Transfusion; Erythropoietin; Health Services Needs and Demand; Humans; Immunosuppressive Agents; Informed Consent; Myelodysplastic Syndromes; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Quality of Life; Thalidomide; Treatment Outcome | 2007 |
Risk-based management of myelodysplastic syndrome.
Topics: Anemia, Sideroblastic; Antilymphocyte Serum; Azacitidine; Benzoates; Decitabine; Deferasirox; DNA Modification Methylases; Enzyme Inhibitors; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Interleukin-11; Iron Chelating Agents; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Prognosis; Risk; Stem Cell Transplantation; Thalidomide; Triazoles | 2007 |
Control of hematopoiesis and apoptosis in MDS: more than FLIPing the coin.
Topics: Antigens, Differentiation; Antineoplastic Agents; Apoptosis; Azacitidine; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Differentiation; Endothelial Cells; Enzyme Inhibitors; Gene Expression Regulation; Hematopoiesis; Hematopoietic Stem Cells; Humans; Lenalidomide; Monocytes; Myelodysplastic Syndromes; Signal Transduction; Stromal Cells; T-Lymphocytes; Thalidomide | 2007 |
Myelodysplasia: the good, the fair and the ugly.
Topics: Antilymphocyte Serum; Antineoplastic Agents; Azacitidine; Bone Marrow Transplantation; Clinical Trials as Topic; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2007 |
Evaluating new treatment options for MDS.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; Epigenesis, Genetic; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Survival Analysis; Thalidomide | 2007 |
[Pathophysiology, diagnosis and treatment of anemia].
Topics: Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Azacitidine; Benzoates; Deferasirox; Diagnosis, Differential; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Thalidomide; Triazoles | 2008 |
[Myelodysplastic syndrome].
Topics: alpha Catenin; Antineoplastic Agents; Azacitidine; Cholecalciferol; Cyclosporine; Decitabine; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Thalidomide; Vitamin K 2; World Health Organization | 2008 |
[Pathogenesis of and therapeutic progress for myelodysplastic syndromes].
Topics: Azacitidine; Clinical Trials as Topic; Decitabine; Deoxycytidine; DNA Methylation; Drug Design; Gene Targeting; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Tumor Necrosis Factor-alpha | 2008 |
Are new agents really making a difference in MDS?
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2008 |
Management of myelodysplastic syndromes: 2008 update.
Topics: Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; Disease-Free Survival; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Survival Analysis; Thalidomide; Treatment Outcome | 2008 |
How I treat patients with myelodysplastic syndromes.
Topics: Acute Disease; Aged; Azacitidine; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Decitabine; Disease Progression; DNA Methylation; Erythropoietin; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid; Myelodysplastic Syndromes; Severity of Illness Index; Thalidomide; Transplantation, Homologous | 2009 |
Optimal sequencing of treatments for patients with myelodysplastic syndromes.
Topics: Azacitidine; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Transplantation, Homologous | 2009 |
Novel biospecific agents for the treatment of myelodysplastic syndromes.
Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Decitabine; Etanercept; Farnesyltranstransferase; Humans; Immunoglobulin G; Lenalidomide; Myelodysplastic Syndromes; Oxides; Receptors, Tumor Necrosis Factor; Thalidomide | 2003 |
[Novel therapeutic agents for myelodysplastic syndrome].
Topics: Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Decitabine; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Humans; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide | 2009 |
Treatment of MDS: something old, something new, something borrowed...
Topics: Azacitidine; Benzoates; Blood Transfusion; Bone Marrow Diseases; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Decitabine; DNA-Cytosine Methylases; Glutathione; Hematinics; Humans; Hydrazines; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Risk; Thalidomide; Thrombopoietin | 2009 |
Pharmacotherapy of myelodysplastic syndromes.
Topics: Azacitidine; Decitabine; DNA Methylation; Drug Approval; Erythropoietin; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Recombinant Proteins; Thalidomide; United States; United States Food and Drug Administration | 2010 |
[Current treatment options for myelodysplastic syndromes].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Blood Transfusion; Bone Marrow Transplantation; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Iron Overload; Lenalidomide; Leukemia, Myeloid, Acute; Long-Term Care; Male; Middle Aged; Myelodysplastic Syndromes; Palliative Care; Thalidomide | 2010 |
Hypomethylating agents and other novel strategies in myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Epoetin Alfa; Erythropoietin; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Recombinant Proteins; Thalidomide; Transplantation, Homologous | 2011 |
Treatment of myelodysplastic syndromes in elderly patients.
Topics: Aged; Anemia, Macrocytic; Antineoplastic Agents; Azacitidine; Blood Component Transfusion; Case Management; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Contraindications; Hematinics; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Immunomodulation; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Palliative Care; Quality of Life; Risk Assessment; Survival Rate; Thalidomide | 2011 |
Cytogenetic and molecular abnormalities in myelodysplastic syndrome.
Topics: Animals; Antineoplastic Agents; Azacitidine; Chromosome Aberrations; Humans; Lenalidomide; Mutation; Myelodysplastic Syndromes; Thalidomide | 2011 |
Treatment of higher-risk myelodysplastic syndrome.
Topics: Algorithms; Antineoplastic Agents; Azacitidine; Combined Modality Therapy; Decitabine; DNA Methylation; Drug Therapy, Combination; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Myelodysplastic Syndromes; Patient Selection; Stem Cell Transplantation; Thalidomide | 2011 |
[Novel therapeutics for myelodysplastic syndromes].
Topics: Azacitidine; Decitabine; DNA Methylation; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2011 |
[MDS].
Topics: Azacitidine; Benzoates; Clinical Trials as Topic; Cytokines; Deferasirox; Drug Therapy, Combination; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Thrombopoietin; Treatment Outcome; Triazoles | 2012 |
[New tools and treatments in myelodysplastic syndromes].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Cytogenetics; Decitabine; Flow Cytometry; Gene Expression Profiling; Humans; Immunologic Factors; Lenalidomide; Mutation; Myelodysplastic Syndromes; Prognosis; Thalidomide | 2013 |
New therapeutics for myelodysplastic syndromes.
Topics: Antineoplastic Agents; Azacitidine; Bone Marrow; Chromosomes, Human, Pair 5; Glycine; Humans; Hydroxamic Acids; Lenalidomide; Myelodysplastic Syndromes; Neoplastic Stem Cells; p38 Mitogen-Activated Protein Kinases; Sequence Deletion; Sulfones; Thalidomide; Transforming Growth Factor beta; Tumor Microenvironment | 2012 |
Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2013 |
Beyond hypomethylating agents failure in patients with myelodysplastic syndromes.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; DNA Methylation; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Prognosis; Recurrence; Retreatment; Thalidomide; Transplantation, Homologous; Treatment Failure; Treatment Outcome | 2014 |
Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.
Topics: Azacitidine; Benzamides; Decitabine; DNA Methylation; Humans; Imatinib Mesylate; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Thalidomide | 2014 |
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles | 2014 |
Update on the pharmacotherapy for myelodysplastic syndromes.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Modification Methylases; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Remission Induction; Risk Assessment; Thalidomide | 2014 |
The myelodysplastic syndromes: the era of understanding.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Erythropoietin; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Myelodysplastic Syndromes; Neoplasm Proteins; Prognosis; Spliceosomes; Thalidomide; Transplantation, Homologous | 2015 |
[Treatment of MDS].
Topics: Allografts; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Autografts; Azacitidine; Enzyme Inhibitors; Erythrocyte Transfusion; Erythropoietin; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Immunologic Factors; Immunosuppressive Agents; Induction Chemotherapy; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Recombinant Proteins; Thalidomide; Transplantation Conditioning | 2014 |
More is better: combination therapies for myelodysplastic syndromes.
Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials as Topic; Decitabine; Disease Progression; Drug Therapy, Combination; Gene Expression; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrimidines; Thalidomide; Valproic Acid; Vorinostat | 2015 |
New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Decitabine; Humans; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Thalidomide; Translational Research, Biomedical | 2015 |
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Decitabine; Disease Management; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Intercellular Signaling Peptides and Proteins; Karyotype; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Research Design; Thalidomide; Transplantation, Homologous | 2015 |
Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure.
Topics: Azacitidine; Drug Resistance; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2016 |
5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).
Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 5; Fatal Outcome; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Translocation, Genetic | 2017 |
Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
Topics: Anemia; Antimetabolites, Antineoplastic; Azacitidine; Chromosomes, Human, Pair 5; Disease Progression; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2017 |
Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Topics: Adult; Azacitidine; Benzoates; Blood Transfusion; Decitabine; Female; Hemorrhage; Humans; Hydrazines; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thalidomide; Thrombocytopenia; Thrombopoietin | 2017 |
Novel therapies in low- and high-risk myelodysplastic syndrome.
Topics: Activin Receptors, Type II; Anemia; Antineoplastic Agents; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Erythrocyte Transfusion; Hematinics; Humans; Immunoglobulin Fc Fragments; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Oligonucleotides; Prognosis; Recombinant Fusion Proteins; Risk Assessment; Stem Cell Transplantation; Sulfonamides; Thalidomide; Thrombopoietin; Transplantation, Homologous | 2019 |
17 trial(s) available for azacitidine and thalidomide
| Article | Year |
|---|---|
Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.
Topics: Aged; Azacitidine; Chromosome Aberrations; DNA Methylation; DNA Modification Methylases; DNA Mutational Analysis; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Karyotyping; Lenalidomide; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Precancerous Conditions; Risk Assessment; Thalidomide; Time Factors; Treatment Outcome; United States | 2010 |
Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Azacitidine; Humans; Lenalidomide; Male; Middle Aged; Risk Factors; Thalidomide | 2011 |
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Cytokines; DNA Methylation; Female; Gene Expression Profiling; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Thalidomide; Treatment Outcome | 2012 |
Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Boronic Acids; Bortezomib; Dexamethasone; DNA Methylation; Doxorubicin; Drug Administration Schedule; Epigenesis, Genetic; Female; Humans; Immunity, Cellular; Lenalidomide; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Plasma Cells; Prospective Studies; Pyrazines; T-Cell Antigen Receptor Specificity; Thalidomide; Transplantation, Autologous | 2012 |
A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dose-Response Relationship, Drug; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Remission Induction; Thalidomide; Young Adult | 2013 |
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; DNA Mutational Analysis; Female; Humans; Karyotyping; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2012 |
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; fms-Like Tyrosine Kinase 3; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Myeloid; Male; Middle Aged; Mutation; Nausea; Nuclear Proteins; Nucleophosmin; Prognosis; Remission Induction; Thalidomide; Treatment Outcome; Vomiting | 2013 |
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Thalidomide | 2013 |
Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Chromosome Banding; Female; Follow-Up Studies; Germany; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Thalidomide; Time Factors; Treatment Outcome | 2013 |
Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Drug Therapy, Combination; Gene Expression; Humans; Immunologic Factors; Interferon-gamma; Interleukin-2; Lenalidomide; Leukemia, Myeloid, Acute; Receptors, Tumor Necrosis Factor, Type II; Recurrence; Remission Induction; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Thalidomide | 2014 |
Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mutation; Nucleophosmin; Thalidomide; Treatment Outcome | 2015 |
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; BH3 Interacting Domain Death Agonist Protein; Biomarkers; Bone Marrow; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retreatment; Thalidomide; Treatment Outcome | 2016 |
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Thalidomide; Treatment Outcome | 2015 |
Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Neoplasm Staging; Quality of Health Care; Survival Analysis; Thalidomide; Treatment Outcome | 2017 |
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antimetabolites; Azacitidine; Bone Marrow; Disease-Free Survival; DNA Methylation; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Quality of Life; Risk; Thalidomide; Treatment Outcome | 2016 |
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Hydroxamic Acids; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Vorinostat | 2017 |
Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial.
Topics: Aged; Aged, 80 and over; Azacitidine; Disease-Free Survival; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Survival Rate; Thalidomide | 2017 |
44 other study(ies) available for azacitidine and thalidomide
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
New agents in the treatment of MDS.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Decitabine; Enzyme Inhibitors; Humans; Indoles; Lenalidomide; Myelodysplastic Syndromes; Predictive Value of Tests; Thalidomide; Treatment Outcome | 2005 |
Myelodysplastic syndromes: introduction.
Topics: Azacitidine; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Intercellular Signaling Peptides and Proteins; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2008 |
Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Cells; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Pilot Projects; Survival Analysis; Thalidomide; Treatment Outcome | 2008 |
The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
Topics: Anemia; Antineoplastic Agents; Azacitidine; Cost of Illness; Costs and Cost Analysis; Darbepoetin alfa; Decision Support Techniques; Deferoxamine; Drug Costs; Drug Therapy; Epoetin Alfa; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Practice Guidelines as Topic; Recombinant Proteins; Siderophores; Thalidomide; United States | 2008 |
[Myelodysplastic syndromes: therapeutic advances and promising future].
Topics: Antineoplastic Agents; Azacitidine; Decitabine; Forecasting; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2008 |
New agents for the treatment of AML recent study findings.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Carbazoles; Clofarabine; Decitabine; Enzyme Inhibitors; Furans; Humans; Hydrazines; Immunotherapy; Lenalidomide; Leukemia, Myeloid, Acute; Quinolones; Staurosporine; Sulfonamides; Thalidomide | 2008 |
Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Azacitidine; Benzene; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Drug Therapy, Combination; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Male; Occupational Exposure; Platelet Count; Quinolones; Thalidomide; Valproic Acid | 2009 |
Durable clinical and cytogenetic remission in an elderly patient with relapsed acute myeloid leukemia treated with low-dose lenalidomide.
Topics: Acute Disease; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Decitabine; Humans; Lenalidomide; Leukemia, Myeloid; Male; Neoplasm Recurrence, Local; Remission Induction; Thalidomide | 2009 |
Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Clinical Trials as Topic; Consensus; Decitabine; Humans; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Prognosis; Risk Factors; Thalidomide | 2008 |
Clinical implications of gene expression profiling in myelodysplastic syndromes: recognition of ribosomal and translational gene dysregulation and development of predictive assays.
Topics: Antigens, CD34; Azacitidine; Cell Proliferation; Decitabine; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Myelodysplastic Syndromes; Protein Biosynthesis; Ribosomes; Thalidomide | 2009 |
Clinical roundtable monograph. Combination therapies for MDS.
Topics: Azacitidine; Carrier Proteins; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colony-Stimulating Factors; Enzyme Inhibitors; Etanercept; Humans; Hydroxamic Acids; Immunoglobulin G; Lenalidomide; Myelodysplastic Syndromes; Platelet Transfusion; Receptors, Fc; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Thalidomide; Thrombopoietin; Valproic Acid; Vorinostat | 2009 |
Management of myelodysplastic syndromes in the geriatric patient.
Topics: Aged; Anemia; Antineoplastic Agents; Azacitidine; Decitabine; Erythrocyte Transfusion; Erythropoietin; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Neutropenia; Thalidomide; Thrombocytopenia | 2009 |
Myelodysplastic syndrome: An update on diagnosis and therapy.
Topics: Antineoplastic Agents; Azacitidine; Cytogenetic Analysis; Decitabine; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Immunohistochemistry; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Severity of Illness Index; Thalidomide | 2009 |
Myelodysplastic syndromes--many new drugs, little therapeutic progress.
Topics: Age Distribution; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Benzoates; Deferasirox; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Survival Analysis; Thalidomide; Triazoles | 2010 |
Novel agents for the treatment of acute myeloid leukemia in the older patient.
Topics: Adenine Nucleotides; Age Factors; Aged; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Clofarabine; Cytosine; Decitabine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Quinolones; Thalidomide | 2011 |
Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Risk; Thalidomide | 2012 |
[A case report of undifferentiated connective tissue disease associated myelodysplastic].
Topics: Azacitidine; Connective Tissue Diseases; Decitabine; Humans; Immunosuppressive Agents; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide | 2012 |
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites; Azacitidine; Benzoates; Chelating Agents; Deferasirox; Drug Eruptions; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematinics; Humans; Iron Overload; Kidney Diseases; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Thalidomide; Treatment Outcome; Triazoles | 2012 |
Improving the outlook for myelodysplastic syndrome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Decitabine; Disease Progression; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Methyltransferases; Molecular Targeted Therapy; Myelodysplastic Syndromes; Phosphoproteins; Point Mutation; Prognosis; Ribonucleoprotein, U2 Small Nuclear; Risk Assessment; RNA Splicing; RNA Splicing Factors; Spliceosomes; Thalidomide | 2012 |
Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.
Topics: Azacitidine; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Treatment Failure; Treatment Outcome | 2013 |
MDS: unraveling the mystery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Thalidomide | 2012 |
[Molecular target therapy for myelodysplastic syndrome].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytokines; Decitabine; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Thalidomide; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2012 |
Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide | 2013 |
Combining gene therapy and fetal hemoglobin induction for treatment of β-thalassemia.
Topics: Antisickling Agents; Azacitidine; beta-Globins; beta-Thalassemia; Decitabine; Fetal Hemoglobin; Genetic Therapy; Genetic Vectors; Humans; Hydroxyurea; Lentivirus; Retroviridae; Thalidomide | 2013 |
[CME myelodysplasia - a frequent hematologic neoplasia in the elderly].
Topics: Aged, 80 and over; Anemia, Aplastic; Azacitidine; Bone Marrow; Bone Marrow Examination; Cell Proliferation; Cell Transformation, Neoplastic; Decitabine; Diagnosis, Differential; Disease Progression; Hematopoiesis; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Thalidomide | 2014 |
[Myelodysplastic syndromes (MDS)].
Topics: Azacitidine; Humans; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Thalidomide | 2014 |
Myelodysplastic syndromes (MDS).
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Immunologic Factors; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2015 |
Decitabine plus thalidomide yields more sustained survival rates than decitabine monotherapy for risk-tailored elderly patients with myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Staging; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Thalidomide | 2015 |
Influence of total genomic alteration and chromosomal fragmentation on response to a combination of azacitidine and lenalidomide in a cohort of patients with very high risk MDS.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Female; Humans; Kaplan-Meier Estimate; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Proportional Hazards Models; Thalidomide; Tumor Suppressor Protein p53 | 2015 |
Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?
Topics: Algorithms; Azacitidine; Clinical Trials as Topic; Decitabine; Drug Approval; Drug Industry; Humans; Karyotyping; Lenalidomide; Methylation; Mutation; Myelodysplastic Syndromes; Prognosis; Risk Assessment; Thalidomide; United States; United States Food and Drug Administration | 2015 |
Autoimmune diseases and myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Azacitidine; Comorbidity; Disease Progression; Disease Susceptibility; Female; Follow-Up Studies; Hashimoto Disease; Humans; Immunocompromised Host; Immunosuppressive Agents; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prevalence; Proportional Hazards Models; Retrospective Studies; Thalidomide; Thyroiditis, Autoimmune; Young Adult | 2016 |
Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation.
Topics: Antigens, CD20; Azacitidine; Cell Line, Tumor; Complement System Proteins; Cytotoxicity, Immunologic; Deoxycytidine; Gemcitabine; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; NF-kappa B; Rituximab; Thalidomide; Up-Regulation | 2016 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid | 2017 |
MODULATION OF ANTITUMOR IMMUNE RESPONSE IN MOUSE PROSTATE CANCER MODEL.
Topics: Animals; Antigens, Neoplasm; Azacitidine; Cell Line, Tumor; Cell Proliferation; Dendritic Cells; Immunologic Factors; Interleukin-12; Interleukin-15; Lenalidomide; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; Prostatic Neoplasms; Thalidomide | 2017 |
JSH Guideline for Tumors of Hematopoietic and Lymphoid Tissues: Leukemia: 6. Myelodysplastic syndromes (MDS).
Topics: Algorithms; Allografts; Azacitidine; Blood Transfusion; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Japan; Lenalidomide; Myelodysplastic Syndromes; Practice Guidelines as Topic; Prognosis; Risk; Thalidomide | 2017 |
Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence.
Topics: Aged; Aged, 80 and over; Azacitidine; Blood Transfusion; Decitabine; Female; Hematinics; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Secondary Prevention; Thalidomide; Time Factors | 2017 |
"Hof" in pronormoblasts: pure erythroid leukemia mimicking plasma cell myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cyclophosphamide; Cytoplasm; Dexamethasone; Diagnostic Errors; Erythroblasts; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Erythroblastic, Acute; Male; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide | 2017 |
Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner.
Topics: Adaptor Proteins, Signal Transducing; Azacitidine; Benzamides; Biphenyl Compounds; Cell Line, Tumor; Chromatin; DNA Methylation; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Gene Expression; Gene Expression Profiling; Humans; Lenalidomide; Morpholines; Multiple Myeloma; Peptide Hydrolases; Pyridones; Thalidomide; Ubiquitin-Protein Ligases | 2018 |
Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States.
Topics: Aged; Aged, 80 and over; Anemia; Azacitidine; Databases, Factual; Decitabine; Electronic Health Records; Enzyme Inhibitors; Female; Hematinics; Humans; Immunologic Factors; Iron Chelating Agents; Lenalidomide; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Proportional Hazards Models; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome; United States | 2018 |
Maintenance therapy with a combination of azacitidine, danazol, and thalidomide after intensive chemotherapy in patients with acute myeloid leukemia.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Danazol; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Thalidomide; Young Adult | 2023 |